ImmunoGen Soars 14% On FDA Breakthrough Designation For Blood Cancer Therapy, , on October 6, 2020 at 5:48 am

By
On October 6, 2020
Tags:

Shares of ImmunoGen spiked 14.2% on Monday after the biotechnology company said that the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to its IMGN632 for the treatment of a rare and aggressive form of blood cancer.ImmunoGen (IMGN) said that “Breakthrough Therapy designation is designed to expedite the development and review of drugs that are intended to treat a serious condition and have generated preliminary clinical evidence that the drug may demonstrate substantial improvement over available therapy.”ImmunoGen’s IMGN632 is an antibody-drug conjugate that targets CD123. The drug therapy is tested in the treatment of relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) – a rare and aggressive form of blood cancer. This form of blood cancer requires intense treatment often followed by stem cell transplant. (See IMGN stock analysis on TipRanks)Following the FDA’s grant announcement, Piper Sandler analyst Joseph Catanzaro said that the company had now another potentially approvable oncology asset. However, Catanzaro remains uncertain about the potential revenue opportunity of the drug. The analyst maintained his Hold rating and a price target of $4.75 (7.5% upside potential) on the stock.Currently, the Street has a cautiously optimistic outlook on the stock. The Moderate Buy analyst consensus is based on 5 Buys and 3 Holds. With shares down 13.5% year-to-date, the average price target of $7.55 implies upside potential of about 70.8% to current levels.Related News: MyoKardia Pops 60% On $13.1B Bristol Myers Takeover Deal Biogen’s Tecfidera Now Faces Cipla Generic Launch; Analyst Wary Pfizer Nabs US Approval For Children’s Oral Arthritis Drug More recent articles from Smarter Analyst: * Accenture Snaps Up Zag To Boost Cloud Capabilities In Australia, New Zealand * Dollar Tree To Add 25,000 Workers In Holiday Season Hiring Spree * Southwest Urges Workers To Take Pay Cuts To Avoid Layoffs * Northern Star, Saracen To Merge To Create $11.5B Gold Miner,

ImmunoGen Soars 14% On FDA Breakthrough Designation For Blood Cancer TherapyShares of ImmunoGen spiked 14.2% on Monday after the biotechnology company said that the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to its IMGN632 for the treatment of a rare and aggressive form of blood cancer.ImmunoGen (IMGN) said that “Breakthrough Therapy designation is designed to expedite the development and review of drugs that are intended to treat a serious condition and have generated preliminary clinical evidence that the drug may demonstrate substantial improvement over available therapy.”ImmunoGen’s IMGN632 is an antibody-drug conjugate that targets CD123. The drug therapy is tested in the treatment of relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) – a rare and aggressive form of blood cancer. This form of blood cancer requires intense treatment often followed by stem cell transplant. (See IMGN stock analysis on TipRanks)Following the FDA’s grant announcement, Piper Sandler analyst Joseph Catanzaro said that the company had now another potentially approvable oncology asset. However, Catanzaro remains uncertain about the potential revenue opportunity of the drug. The analyst maintained his Hold rating and a price target of $4.75 (7.5% upside potential) on the stock.Currently, the Street has a cautiously optimistic outlook on the stock. The Moderate Buy analyst consensus is based on 5 Buys and 3 Holds. With shares down 13.5% year-to-date, the average price target of $7.55 implies upside potential of about 70.8% to current levels.Related News: MyoKardia Pops 60% On $13.1B Bristol Myers Takeover Deal Biogen’s Tecfidera Now Faces Cipla Generic Launch; Analyst Wary Pfizer Nabs US Approval For Children’s Oral Arthritis Drug More recent articles from Smarter Analyst: * Accenture Snaps Up Zag To Boost Cloud Capabilities In Australia, New Zealand * Dollar Tree To Add 25,000 Workers In Holiday Season Hiring Spree * Southwest Urges Workers To Take Pay Cuts To Avoid Layoffs * Northern Star, Saracen To Merge To Create $11.5B Gold Miner

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

+65 3105 1295

Taiwan

Coming Soon!

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462